Today, we will see why Selecta Biosciences (SELB) is an attractive pick in March 2020.
Company overview
Selecta Biosciences is a clinical-stage biopharmaceutical company focused on overcoming immunogenicity associated with biologic therapies. The company is deploying its proprietary platform, ImmTOR (Selective Immune Tolerance Technology) to promote selective tolerance of biologic therapies. This, in turn, will improve the efficacy and safety of these therapies. The company's lead product, SEL-212, is currently being evaluated in Phase 2 clinical trials for the treatment of chronic refractory gout. The company is also studying the potential of ImmTOR in overcoming